Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

NCNA
NuCana plc
stock NASDAQ ADR

At Close
May 16, 2025 3:59:30 PM EDT
0.0435USD-18.539%(-0.0099)116,940,389
0.00Bid   0.00Ask   0.0000Spread
Pre-market
May 16, 2025 9:28:30 AM EDT
0.0492USD-7.865%(-0.0042)19,508,074
After-hours
May 16, 2025 4:58:30 PM EDT
0.0451USD+3.563%(+0.0016)1,810,322
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Nov 24, 2021
06:14AM EST  HC Wainwright & Co. Maintains Buy on NuCana, Lowers Price Target to $9   Benzinga
Nov 18, 2021
04:03PM EST  NuCana Q3 (0.15) vs (0.24) In   Benzinga
04:01PM EST  Enrolled Required Number of Patients to Conduct First Interim Analysis in Phase 3 Biliary Tract Cancer Study in the First Half of 2022   GlobeNewswire Inc
Nov 10, 2021
08:00AM EST  NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies 2021 London Healthcare Conference.   GlobeNewswire Inc
Nov 1, 2021
04:01PM EDT  NuCana Appoints Elliott M. Levy, M.D. to its Board of Directors   GlobeNewswire Inc
Sep 29, 2021
02:30PM EDT  Mid-Afternoon Market Update: Dow Surges Over 200 Points; Neonode Shares Spike Higher   Benzinga
12:20PM EDT  Mid-Day Market Update: Nasdaq Edges Lower; NuCana Shares Jump   Benzinga
11:12AM EDT  NuCana Plc (NCNA) shares are surging on Wednesday morning trade after the said it received fast track designation from FDA for Acelarin for the treatment of biliary tract cancer. The investigative drug compound is currently pursued in the phase 3 study.   RTTNews
10:27AM EDT  Mid-Morning Market Update: Markets Open Higher; Jabil Reports Mixed Q1 Results   Benzinga
08:06AM EDT  NuCana Receives FDA Fast Track Designation For Acelarin (NUC-1031) For Treatment Of Biliary Tract Cancer   Benzinga
08:00AM EDT  NuCana Receives Fast Track Designation from the U.S. Food and Drug   GlobeNewswire Inc
Sep 16, 2021
08:10AM EDT  NuCana Announces Four Poster Presentations At ESMO Congress 2021 Sept. 16-21   Benzinga
08:00AM EDT  NUC-3373 Continues to Demonstrate Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer   GlobeNewswire Inc
Sep 15, 2021
08:02AM EDT  NuCana Reports Enrollment Of Required Number Of Patients To Conduct First Interim Analysis In Phase 3 Biliary Tract Cancer Study   Benzinga
08:00AM EDT  Enrollment of 418 Evaluable Patients Expected to Enable First Interim Analysis in the First Half of 2022   GlobeNewswire Inc
Sep 1, 2021
08:00AM EDT  NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will participate in three upcoming virtual investor conferences.   GlobeNewswire Inc
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 19, 2021
04:53PM EDT  NuCana Files For Mixed-Securities Shelf Of Up To $400M   Benzinga
04:53PM EDT  NuCana Files For Mixed-Securities Shelf Shelf Of Up To $400M   Benzinga
04:03PM EDT  NuCana Reports Q2 EPS (0.17) Up From   Benzinga
04:01PM EDT  NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2021 and provided an update on its broad clinical program with its transformative ProTide therapeutics.   GlobeNewswire Inc
Aug 10, 2021
08:00AM EDT  NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Jeffrey D. Bloss, M.D. as Chief Medical Officer. Dr. Bloss will be based in NuCanas US offices located outside Boston, MA.   GlobeNewswire Inc
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 14, 2021
07:48AM EDT  The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues   Benzinga
Jul 7, 2021
07:41AM EDT  The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend   Benzinga
Jun 10, 2021
12:08PM EDT  Mid-Day Market Update: Yiren Digital Rises Following Q1 Results; Ocugen Shares Slide   Benzinga
Jun 2, 2021
08:20AM EDT  The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements   Benzinga
May 25, 2021
08:00AM EDT  NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual Healthcare Conference being held from June 1 to June 4, 2021.   GlobeNewswire Inc
May 19, 2021
04:03PM EDT  NuCana Q1 EPS (0.19), Down From (0.12) YoY; Had Cash And Equivalents Of 78.6M As Of Mar. 31   Benzinga
04:01PM EDT  NuCana Reports First Quarter 2021 Financial Results and Provides   GlobeNewswire Inc
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 13, 2021
08:10AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use   Benzinga
May 11, 2021
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 6, 2021
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
May 5, 2021
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
Apr 28, 2021
08:00AM EDT  NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one-on-one meetings at the 7th Annual Truist Securities Life Sciences Summit being held virtually from May 4 to May 5, 2021.   GlobeNewswire Inc
Apr 21, 2021
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
Apr 19, 2021
04:23PM EDT  Nucana Plc On Apr 16, Initiated Legal Proceedings Against Gilead Sciences Ireland UC And Gilead Sciences GmbH For Patent Infringement   Benzinga
Apr 12, 2021
10:16AM EDT  NuCana Saturday Morning Announced 5 Poster Presentation At American Association For Cancer Research Conference   Benzinga
Apr 10, 2021
08:30AM EDT  -- NUC-3373 Shows Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer   GlobeNewswire Inc
Mar 4, 2021
04:02PM EST  Nucana Q4 EPS (0.24), Same YoY   Benzinga
04:01PM EST  NuCana Reports Fourth Quarter and Year-End 2020 Financial   GlobeNewswire Inc
Feb 25, 2021
08:00AM EST  NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will participate in the following conferences:   GlobeNewswire Inc
Jan 15, 2021
08:06AM EST  NuCana Presents Encouraging Data At ASCO GI For NUC-3373 In Heavily Pre-Treated Patients With Metastatic Colorectal Cancer   Benzinga
08:01AM EST  Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patients who had Progressed on Prior Fluoropyrimidine Therapy   GlobeNewswire Inc
Jan 12, 2021
11:43AM EST  AcelRx, NuCana Shares Spike Higher; Traders Circulate Tipranks Article Titled 'These 2 Penny Stocks Could Surge Over 300%, Say Analysts'   Benzinga
Dec 21, 2020
04:01PM EST  Pharmaceutical Executive Brings a Wealth of Experience to NuCanas Board of Directors   GlobeNewswire Inc
Dec 1, 2020
08:20AM EST  10 Biggest Price Target Changes For Tuesday   Benzinga
08:08AM EST  The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit   Benzinga
06:32AM EST  HC Wainwright & Co. Maintains Buy on NuCana, Lowers Price Target to $10   Benzinga
Nov 30, 2020
04:01PM EST  Final Data from the Phase Ib Study of Acelarin plus Cisplatin in Patients with Advanced Biliary Tract Cancer Published Online Ahead of Print in The Oncologist   Benzinga
04:01PM EST  Acelarin plus Cisplatins High Objective Response Rate and Favorable Safety Profile Confirmed   GlobeNewswire Inc
Nov 24, 2020
08:41AM EST  10 Biggest Price Target Changes For Tuesday   Benzinga
06:24AM EST  HC Wainwright & Co. Maintains Buy on NuCana, Lowers Price Target to $15   Benzinga
Nov 19, 2020
04:05PM EST  NuCana Q3 EPS GBP (0.24) Down From GBP (0.13) YoY   Benzinga
04:01PM EST  NuCana Reports Third Quarter 2020 Financial Results and Provides   GlobeNewswire Inc
Nov 17, 2020
04:01PM EST  NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Piper Sandler 32nd Annual Healthcare Conference being held virtually from December 1 to December 3, 2020.   GlobeNewswire Inc
Nov 12, 2020
04:01PM EST  NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual London Healthcare Conference.   GlobeNewswire Inc
Oct 22, 2020
11:11AM EDT  Benzinga's Top Upgrades, Downgrades For October 22, 2020   Benzinga
07:40AM EDT  Truist Securities Initiates Coverage On NuCana with Buy Rating, Announces Price Target of $22   Benzinga
Oct 13, 2020
04:01PM EDT  NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Bali Muralidhar, M.D., Ph.D. to its Board of Directors.   GlobeNewswire Inc
Sep 23, 2020
02:57PM EDT  Mid-Afternoon Market Update: Dow Tumbles 400 Points; JinkoSolar Shares Jump   Benzinga
Sep 21, 2020
04:02PM EDT  Encouraging Efficacy Signals Observed in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer in the Phase Ib Study of NUC-3373 (NuTide:302)   GlobeNewswire Inc
04:01PM EDT  NuCana Announces Closing of Public Offering of American Depositary   GlobeNewswire Inc
Sep 17, 2020
11:16AM EDT  Why NuCana's Stock Is Trading Lower Today   Benzinga
07:10AM EDT  NuCana Prices Underwritten Public Offering Of ~15.56M American Depositary Shares At A Price To Public Of $4.50 Per ADS   Benzinga
07:00AM EDT  NuCana Announces Pricing of a Public Offering of American   GlobeNewswire Inc
Sep 16, 2020
06:39PM EDT  After Market Hours: Herman Miller, Switchback Energy,   RTTNews
04:02PM EDT  NuCana Announces Proposed Public Offering Of American Depositary Shares; Size Not Disclosed   Benzinga
04:01PM EDT  NuCana Announces Proposed Public Offering of American Depositary   GlobeNewswire Inc
Aug 21, 2020
06:42AM EDT  HC Wainwright & Co. Maintains Buy on NuCana, Raises Price Target to $17   Benzinga
Aug 19, 2020
04:03PM EDT  NuCana Q2 EPS GBP $(0.19) Down From GBP $(0.14) YoY   Benzinga
04:02PM EDT  NuCana Q2 EPS $(0.19) Down From $(0.14) YoY   Benzinga
04:01PM EDT  NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2020 and provided an update on its broad clinical program with its transformative ProTide therapeutics.   GlobeNewswire Inc
Jul 24, 2020
03:25PM EDT  Benzinga's Top Upgrades, Downgrades For July 24, 2020   Benzinga
12:00PM EDT  Oppenheimer Initiates Coverage On NuCana with Outperform Rating, Announces Price Target of $20   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC